Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01189 (beta-endorphin)
 21,003 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Delta-sleep-inducing peptide (DSIP)-like material was detected in human breast milk of two women by RIA with a recovery of about 90%. The high concentration of DSIP-like immunoreactivity (DSIP-LI) in colostrum (30 ng/ml) decreased to about 10 ng/ml in milk. The concentration continued to decrease over the next 2 months in one women. In the same woman, a significant circadian rhythm of the amount of breast milk DSIP was found with the peak in the afternoon and the trough in the morning. A significant effect of the sampling procedure was detected in the other woman examined; lower amounts of DSIP-LI were found when the milk was collected before and higher concentrations after nursing. Gel chromatography revealed that most of the immunoreactive DSIP-LI in milk and colostrum occurred in a form larger than the nonapeptide. The presence of DSIP itself, however, was demonstrated by high pressure liquid chromatography, which also showed additional peptides reacting with the antibody. Digestion of the large immunoreactive DSIP-LI by trypsin produced a peak on Sephadex G-10 that coeluted with DSIP. This peak contained three immunoreactive fractions with retention times on high pressure liquid chromatography similar to DSIP, phosphorylated DSIP, and N-tyrosine-DSIP. Plasma samples taken during pregnancy were assayed for DSIP but no difference from normal values was found. Slightly higher amounts were found in placenta than in blood, which might be due to interfering substances. No Tyr-MIF-1 or corticotropin-releasing hormone was detected by RIA in human breast milk. Peptides and proteins of milk can be absorbed from the gastrointestinal tract of babies, but it is not known if the DSIP-LI in human milk is involved in the induction of a sleep-wake cycle in neonates.
 ...
PMID:Presence of delta-sleep-inducing peptide-like material in human milk. 654 44

Despite the existence of a large body of information on the subject, the mechanisms of opiate tolerance and dependence are not yet fully understood. Although the traditional mechanisms of receptor down-regulation and desensitization seem to play a role, they cannot entirely explain the phenomena of tolerance and dependence. Therefore, other mechanisms, such as the presence of antiopiate systems and the coupling of opiate receptors to alternative G-proteins, should be considered. A further complication of studies of opiate tolerance and dependence is the multiplicity of endogenous opiate receptors and peptides. This review will focus on the endogenous opioid system--peptides, receptors, and coupling of receptors to intracellular signaling via G-proteins--in the context of their roles in tolerance and dependence. Opioid peptides include the recently discovered endomorphins and those encoded by three known genes--pro-opiomelanocortin, pro-enkephalin, and pro-dynorphin. They bind to three types of receptors--mu, delta, and kappa. Each of the receptor types is further divided into multiple subtypes. These receptors are widely known to be coupled to G-proteins of the Gi and Go subtypes, but an increasing body of results suggests coupling to other G-proteins, such as Gs. The coupling of opiate receptors to Gs, in particular, has implications for tolerance and dependence. Alterations at the receptor and transduction level have been the focus of many studies of opiate tolerance and dependence. In these studies, both receptor down-regulation and desensitization have been demonstrated in vivo and in vitro. Receptor down-regulation has been more easily observed in vitro, especially in response to morphine, a phenomenon which suggests that some factor which is missing in vitro prevents receptors from down-regulating in vivo and may play a critical role in tolerance and dependence. We suggest that antiopiate peptides may operate in vivo in this capacity, and we outline the evidence for the antiopiate properties of three peptides: neuropeptide FF, orphanin FQ/nociceptin, and Tyr-W-MIF-1. In addition, we provide new results suggesting that Tyr-W-MIF-1 may act as an antiopiate at the cellular level by inhibiting basal G-protein activation, in contrast to the activation of G-proteins by opiate agonists.
 ...
PMID:Opiate tolerance and dependence: receptors, G-proteins, and antiopiates. 986 69

1. Studies, using a wide variety of stressors, have clearly indicated that the pattern of neuroendocrine response is dependent upon the stress stimulus applied. 2. The Tyr-MIF-1 family of peptides (Tyr-MIF-1s) includes MIF-1, Tyr-MIF-1, Tyr-W-MIF-1 and Tyr-K-MIF-1. These neuropeptides, neuromodulators are able to inhibit the expression of some forms of stress-induced analgesia. 3. The aim of this study was to compare changes in ACTH and corticosterone (CORT) concentration after various stressors (immobilization, cold and heat), as well as after injection of investigated Tyr-MIF-1s peptides. 4. According to our results, hypothalamic-pituitary-adrenal (HPA) system was activated by all the stressors applied. Heat and immobilization are stronger stressors, as the exposure of animals to a high ambient temperature and immobilization resulted in the highest rise of plasma ACTH and CORT concentration when compared with cold stress. Moreover, all the investigated peptides from Tyr-MIF-1 family, administered after application of stressors, inhibited the elevations in adrenocorticotropic hormone (ACTH) and corticosterone (CORT) plasma concentrations significantly. 5. In conclusion, the various stressors applied seem to induce a different response of the HPA system as judged by quantitative changes in ACTH and CORT release. We suggest that Tyr-MIF-1 peptides may possess anti-stressor effects, as they inhibited stress-induced rising in two hormones that were investigated.
 ...
PMID:Effect of Tyr-MIF-1 peptides on blood ACTH and corticosterone concentration induced by three experimental models of stress. 1879 7


<< Previous 1 2 3